Alan Matsumoto is a Rheumatology/Immunology physician affiliated with Arthritis and Rheumatism Associates. OpenAlex indexes 22 publications with 1,019 citations (h-index 14); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2730 University Blvd W
Suite 310
Wheaton, MD 209021905
Telephone
301-942-7600Provider last certified this registry record 11 Mar 2021.
Clinical trials
- VALOR: The Talent Thoracic Stent Graft System Clinical Study
Sponsor: Medtronic Cardiovascular
- Benefits of Medical Therapy Plus Stenting for Renal Atherosclerotic Lesions
Sponsor: Baim Institute for Clinical Research
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
17 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novartis Pharmaceuticals CorporationProgram year202536 payments
- Janssen Scientific Affairs, LLCProgram year202536 payments
- PFIZER INC.Program year202516 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
52.5%Interleukin-6 Receptor Antagonist29.3%Tocilizumab100%Actemra0%Part D + Part B<11 patientsTNF inhibitor12.3%Golimumab79%Infliximab20%Enbrel Sureclick1%Humira(Cf) Pen0%Enbrel0%Humira Pen0%Part D + Part B<11 patients+ 6 more classes in this area
Musculoskeletal
43.9%Other drugs affecting bone structure and mineralization23.7%Romosozumab-aqqg100%Part B, office-administered≥43 patientsRANK Ligand Inhibitor19.9%Denosumab100%Part B, office-administered≥343 patients+ 5 more classes in this area
Dermatology
2.9%Corticosteroid2.9%Methylprednisolone acetate80%Methylprednisolone sodium succinate20%Methylprednisolone1%Part D + Part B≥69 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Marc Hochberg, MD
University of Maryland School of Medicine
Michelle Petri, MD
Johns Hopkins University School of Medicine
Dinesh Khanna, MD
University of Michigan
Matthew Liang, MD
Brigham and Women's Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”